Percheron licenses HMBD-002 from Hummingbird Bioscience

Percheron Therapeutics has licensed HMBD-002, a phase II-ready immunooncology drug candidate, from Hummingbird Bioscience.

This monoclonal antibody therapy targets VISTA and has completed a phase I clinical trial in the United States. Percheron plans to initiate a clinical trial in 2026. The agreement includes upfront payments, milestone payments, and royalties on net sales. This partnership marks a transformative step for Percheron, as they refocus their pipeline after recent challenges. They aim to bring HMBD-002 through phase II trials towards commercialization, addressing unmet medical needs in oncology. Investors can expect further updates in the coming months.